Home / Insights / Conducting Clinical Trials in Africa: Key Operational Considerations
Clinical Trials in Africa
Conducting Clinical Trials in Africa: Key Operational Considerations
Conducting clinical trials in Africa fails most often when a global plan is pasted onto a continent and called local adaptation. Regulatory timelines, ethics pathways, import rules, site capability and the simple logistics of a monitoring visit are not the same in Johannesburg, Abidjan and Yaoundé.
Leadership experience across 13 African markets is useful only if it is used that way: as a reason to plan each country, not as a claim that the continent is familiar. Clinical trials in Africa reward sponsors who ask what is different before they lock the milestone.
Where plans usually break
CTA and ethics sequences are a common break. So is the assumption that a CRO's regional hub can see site-level trouble early enough. Import of investigational product, label language, source document practice, and the availability of a monitor who can actually reach the site all change the critical path.
Regulatory and market support is the practical companion to that planning: landscape, dossier review, and country-specific operations, not a generic Africa slide.
International teams often need the longer view in what sponsors should know before conducting trials in Africa.